ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors

Xiao, Lu-Shan; Li, Qi-Mei; Hu, Cheng-Yi; Cui, Hao; Hong, Chang; Huang, Chao-Yi; Li, Rui-Ning; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*南方医科大学; 1
Annals of Palliative Medicine2021-11DOI: 10.21037/apm-21-2023
7被引7阅读
引用收藏
分享

摘要

Background: At present, some cancer patients experience hyperprogressive disease (HPD) after receiving immunotherapy. This study used the Response Evaluation Criteria in Solid Tumors 1.1 to evaluate the incidence of HPD in patients receiving immune checkpoint inhibitors (ICIs) for treating primary liver cancer (PLC) and to explore the risk factors for HPD. @@@ Methods: This retrospective, single-center study included patients with PLC who were treated with ICIs. The RECIST 1.1 was used to determine patients with HPD. Univariate and multivariate regression analyses were performed to explore the risk factors for HPD, and clinical variables with prognostic significance for HPD were included to establish a risk model. @@@ Results: Among 129 patients with PLC treated with ICIs, HPD occurred in 13 patients (10.1%). In the multivariate regression analysis, lymph node metastasis and lung metastasis were risk factors for HPD. The area under the curve of the risk model, established by including lymph node metastasis, lung metastasis, neutrophil-lymphocyte ratio, albumin, and performance status, was 0.801 (P<0.001). The progression-free survival of HPD patients was significantly worse than that of non-HPD patients (P<0.001). @@@ Conclusions: In this study, 10.1% of patients with PLC had HPD. Compared with the non-HPD patients, lung metastasis and lymph node metastasis were independent risk factors of HPD.

学科与关键词

关键词
Immune checkpoint inhibitors (ICIs)lymphatic metastasislung neoplasmsliver neoplasmsregression analysis
相关
加载中…
  • Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy
    Zhang, Lu*; Wu, Lingeng; Chen, Qiuying; Zhang, Bin; Liu, Jing; Liu, Shuyi; Mo, Xiaokai; Li, Minmin; Chen, Zhuozhi; Chen, Luyan; You, Jingjing; Jin, Zhe; Chen, Xudong*; Zhou, Zejian*; Zhang, Shuixing*ECLINICALMEDICINE, 2021, 31: 100673.被引 23
  • Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors
    Hong, Chang; Dong, Han-Zhi; Li, Rui-Ning; Zhu, Hong-Bo; Li, Qi-Mei; Cui, Hao; Hu, Cheng-Yi; Huang, Chao-Yi; Peng, Jie; Liu, Li*; Zou, Xue-Jing*; Xiao, Lu-Shan*DIGESTIVE DISEASES, 2023, 41(3): 422-430.被引 3
  • Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors
    Xiao, Lu-Shan; Hu, Cheng-Yi; Cui, Hao; Li, Rui-Ning; Hong, Chang; Li, Qi-Mei; Huang, Chao-Yi; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li*Cancer Medicine, 2022, 11(24): 4880-4888.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Palliative Medicine
发表日期
2021-11
卷期
第 10 卷, 第 11 期
页码
11244-+
DOI
10.21037/apm-21-2023
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Nature Science Foundation of China [81773008, 81972897]; Clinical Research Startup Program of Southern Medical University via the High-level University Construction Funding of the Guangdong Provincial Department of Education [LC2019ZD003]

作者

  • X

    Xiao, Lu-Shan (第一作者)

    southern med univ

  • L

    Li, Qi-Mei

    southern med univ

查看全部 10 位作者收起作者
  • H

    Hu, Cheng-Yi

    southern med univ

  • C

    Cui, Hao

    southern med univ

  • H

    Hong, Chang

    southern med univ

  • H

    Huang, Chao-Yi

    southern med univ

  • L

    Li, Rui-Ning

    southern med univ

  • D

    Dong, Zhong-Yi

    southern med univ

  • Z

    Zhu, Hong-Bo

    1 · univ south china

  • L

    Liu, Li (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417